CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts
Key Points
In a landmark decision, the Central Drugs Standard Control Organisation (CDSCO) has approved India's first dengue vaccine, Qdenga®, marking a significant advancement in public health strategy against dengue. This development is crucial for UPSC aspirants, especially for GS Paper 2 (Governance, Health) and GS Paper 3 (Science and Technology). Last Updated: 22-07-2026
Key Facts About Qdenga®
- Qdenga® is a live, attenuated tetravalent dengue vaccine.
- Developed using recombinant DNA technology, it targets all four dengue virus serotypes.
- The vaccine is indicated for individuals aged 4 to 60 years.
- Administered in two doses of 0.5 ml each, three months apart.
- Approved under the provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945.
- Received regulatory approval in 42 countries, including the European Union and WHO prequalification.
- Over 24 million doses distributed globally with a favorable safety profile.
India's Public Health Milestone
The approval of Qdenga® is a significant milestone in India's public health response to dengue, aligning with the country's strategic goals of enhancing healthcare access and disease prevention. This aligns with India's broader objectives of reducing disease burden and improving health outcomes, contributing to economic growth and social well-being. The vaccine's global acceptance underscores India's commitment to adopting international health standards.
UPSC Relevance
This topic is relevant for GS Paper 2 (Governance, Health) and GS Paper 3 (Science and Technology, Biotechnology). In prelims, questions may focus on the vaccine's features, approval process, and global status. For mains, discussions could revolve around public health strategies, vaccine development, and international health collaborations. It may also be relevant for essays on public health advancements.
FAQ Section
- What is Qdenga®? Qdenga® is a live, attenuated tetravalent dengue vaccine developed to prevent dengue disease in individuals aged 4 to 60 years.
- Why is Qdenga® important? It represents a significant step in India's public health strategy, aiming to reduce the incidence of dengue through vaccination, complementing existing control measures.
- What are the key features of Qdenga®? The vaccine targets all four dengue virus serotypes, is administered in two doses, and has been approved in 42 countries, including WHO prequalification.
Detailed Coverage
- CDSCO grants marketing authorization for Qdenga®.
- First dengue vaccine approved in India.
- Manufactured by Takeda GmbH, Germany.
- Vaccine developed using recombinant DNA technology.
- Indicated for individuals aged 4 to 60 years.
- Administered in two doses of 0.5 ml each.
- Evaluated through extensive global clinical trials.
- Conducted in over eight countries, including Brazil and Thailand.
- Received regulatory approval in 42 countries.
- WHO prequalification obtained.
- Over 24 million doses distributed globally.
- Favorable safety profile with no significant concerns.
- Complements ongoing national dengue control measures.
- Supports public health response to dengue.
- Ensures access to safe and effective vaccines.
- Part of the National Vector Borne Disease Control Programme.